FMS-like tyrosine kinase 3 inhibitors: a patent review

Bibliography

• Matthews W, Jordan CT, Wiegand GW, A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991;65:1143-52
   PubMed Web of Science ®Google Scholar
• Namikawa R, Muench MO, Roncarolo MG. Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells 1996;14:388-95
   PubMed Web of Science ®Google Scholar
• Shurin MR, Esche C, Lotze MT. FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev 1998;9:37-48
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-18
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S, Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12:1333-7
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-9
   PubMed Web of Science ®Google Scholar
• Mckenzie SB. Advances in understanding the biology and genetics of acute myelocytic leukemia. Clin Lab Sci 2005;18:28-37
   PubMedGoogle Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62
   PubMed Web of Science ®Google Scholar
• Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol 2010;3:17
   PubMed Web of Science ®Google Scholar
• Birg F, Courcoul M, Rosnet O, Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992;80:2584-93
   PubMed Web of Science ®Google Scholar
• Carow CE, Levenstein M, Kaufmann SH, Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996;87:1089-96
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Woods WG, Stirewalt DL, Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97:89-94
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005;19:1345-9
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Krauter J, Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-84
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients. Blood 2008;111:2527-37
   PubMed Web of Science ®Google Scholar
• Horiike S, Yokota S, Nakao M, Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997;11:1442-6
   PubMed Web of Science ®Google Scholar
• Taketani T, Taki T, Sugita K, FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004;103:1085-8
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-45
   PubMed Web of Science ®Google Scholar
• Stone R, Fischer T, Paquette R, A Phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have flt3 mutations is similar to those with wild-type FLT3 [abstract 634]. 51st American Society of Hematology (ASH) annual meeting and exposition; 5 – 8 December 2009; New Orleans, USA
   Google Scholar
• Astex Therapeutics. Pharmaceutical combinations. WO2008001101; 2008
   Google Scholar
• Howard S, Berdini V, Boulstridge JA, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
   PubMed Web of Science ®Google Scholar
• Kasper S, Breitenbuecher F, Hoehn Y, The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk Res 2008;32:1698-708
   PubMed Web of Science ®Google Scholar
• Grunberger T, Demin P, Rounova O, Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood 2003;102:4153-8
   PubMed Web of Science ®Google Scholar
• Lipka DB, Hoffmann LS, Heidel F, LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008;7:1176-84
   PubMed Web of Science ®Google Scholar
• Chao Q, Sprankle KG, Grotzfeld RM, Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2 ,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem 2009;52:7808-16
   PubMed Web of Science ®Google Scholar
• Zarrinkar PP, Gunawardane RN, Cramer MD, AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-92
   PubMed Web of Science ®Google Scholar
• Cortes J, Foran J, Ghirdaladze D, AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study [abstract 636]. 51st American society of hematology (ASH) annual meeting and exposition; 5 – 8 December 2009; New Orleans, USA
   Google Scholar
• Guerrouahen BS, Futami M, Vaklavas C, Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010;16:1149-58
   PubMed Web of Science ®Google Scholar
• Auclair D, Miller D, Yatsula V, Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007;21:439-45
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62
   PubMed Web of Science ®Google Scholar
• Sugen. Indolinone compounds for the treatment of disease. WO1996040116; 1996
   Google Scholar
• Yee KW, O'farrell AM, Smolich BD, SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002;100:2941-9
   PubMed Web of Science ®Google Scholar
• Fiedler W, Mesters R, Tinnefeld H, A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763-7
   PubMed Web of Science ®Google Scholar
• Patyna S, Laird AD, Mendel DB, SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5:1774-82
   PubMed Web of Science ®Google Scholar
• Sugen. Pyrrole substituted 2-indolinone protein kinase inhibitors. WO2001060814; 2001
   Google Scholar
• Yamanouchi Pharmaceutical. Pharmaceutical composition containing 3-quinolin-2(1h)-ylidene indolin-2-one derivative as active component. JP2005145928; 2005
   Google Scholar
• Amino N, Ideyama Y, Yamano M, YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res 2006;12:1630-8
   PubMed Web of Science ®Google Scholar
• Anygen. Indirubin derivatives having anticancer property against human cancer cell me. WO2005070416; 2005
   Google Scholar
• Choi SJ, Moon MJ, Lee SD, Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells. Bioorg Med Chem Lett 2010;20:2033-7
   PubMed Web of Science ®Google Scholar
• Industrial Technology Research Institute. Azulene compounds. EP1918277; 2008
   Google Scholar
• Ko CH, Chen CH, Lee O, K01109, a potent, novel selective FLT-3 inhibitor for the treatment of acute myelogenous leukemia [abstract LB-219]. 2009 AACR Annual Meeting; 18 – 22 April 2009; Denver, USA
   Google Scholar
• Johannes-Gutenberg Universitat Mainz. Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management. WO2009071620; 2009
   Google Scholar
• Teller S, Kramer D, Bohmer SA, Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002;16:1528-34
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kogyo. Indazole derivatives. WO2005012257; 2005
   Google Scholar
• Shiotsu Y, Kiyoi H, Ishikawa Y, KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17
   PubMed Web of Science ®Google Scholar
• Cortes J, Roboz GJ, Kantarjian H, A phase i dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML [abstract 2967]. 50th American society of hematology (ASH) annual meeting and exposition; 6 – 9 December 2008; San Francisco, USA
   Google Scholar
• Pratz KW, Cortes J, Roboz GJ, A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938-46
   PubMed Web of Science ®Google Scholar
• Abbott. Indazole, benzisoxazole, and benzisothiazole kinase inhibitors. WO2004113304; 2004
   Google Scholar
• Zhou J, Goh BC, Albert DH, Chen CS. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2009;2:33
   PubMed Web of Science ®Google Scholar
• Zhou J, Pan M, Xie Z, Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 2008;22:138-46
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Pyrrolotriazine kinase inhibitors. WO2007061882; 2007
   Google Scholar
• SuperGen. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors. WO2008058126; 2008
   Google Scholar
• Chen LS, Redkar S, Bearss D, Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150-7
   PubMed Web of Science ®Google Scholar
• Ariad Pharmaceuticals. Bicyclic heteroaryl compounds. WO2007075869; 2007
   Google Scholar
• Amphora. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof. WO2005033102; 2005
   Google Scholar
• The Pfahl Family Trust. Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases. WO2006130613; 2006
   Google Scholar
• Novartis. Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors. WO2005047273; 2005
   Google Scholar
• IRM. Compounds and compositions as protein kinase inhibitors. WO2006081172; 2006
   Google Scholar
• Sugen. Treatment of platelet derived growth factor related disorders such as cancers. US5990141; 1999
   Google Scholar
• Tse KF, Novelli E, Civin CI, Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001;15:1001-10
   PubMed Web of Science ®Google Scholar
• Levis M, Tse KF, Smith BD, A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001;98:885-7
   PubMed Web of Science ®Google Scholar
• Gazit A, App H, Mcmahon G, Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem 1996;39:2170-7
   PubMed Web of Science ®Google Scholar
• Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 1989;32:2344-52
   PubMed Web of Science ®Google Scholar
• Tse KF, Allebach J, Levis M, Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002;16:2027-36
   PubMed Web of Science ®Google Scholar
• Yissum Research Development Company of the Hebrew University of Jerusalem. PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same. WO2001034607; 2001
   Google Scholar
• Gazit A, Yee K, Uecker A, Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003;11:2007-18
   PubMed Web of Science ®Google Scholar
• Cor Therapeutics and Kyowa Hakko Kogyo. Quinazoline derivatives as kinase inhibitors. WO2002016351; 2002
   Google Scholar
• Kelly LM, Yu JC, Boulton CL, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002;1:421-32
   PubMed Web of Science ®Google Scholar
• Pandey A, Volkots DL, Seroogy JM, Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 2002;45:3772-93
   PubMed Web of Science ®Google Scholar
• Deangelo DJ, Stone RM, Heaney ML, Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-81
   PubMed Web of Science ®Google Scholar
• Clark JJ, Cools J, Curley DP, Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004;104:2867-72
   PubMed Web of Science ®Google Scholar
• Astrazeneca. Combination therapy for the treatment of cancer. WO2007132215; 2007
   Google Scholar
• Oke A, Pearce D, Wilkinson RW, AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009;69:4150-8
   PubMed Web of Science ®Google Scholar
• Grundy M, Seedhouse C, Shang S, The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 2010;9:661-72
   PubMed Web of Science ®Google Scholar
• Janssen. Synergistic modulation of Flt3 kinase using alkylquinolines and alkylquinazolines. WO2006135629; 2006
   Google Scholar
• Signal Pharmaceuticals. Quinazoline analogs and related compounds and methods for treating inflammatory conditions. US5939421; 1999
   Google Scholar
• Frelin C, Imbert V, Griessinger E, Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005;105:804-11
   PubMed Web of Science ®Google Scholar
• Griessinger E, Imbert V, Lagadec P, AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. Leukemia 2007;21:877-85
   PubMed Web of Science ®Google Scholar
• Kirin. Quinoline and quinazoline derivatives and drugs containing the same. WO2001047890; 2001
   Google Scholar
• Kirin. Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of Flt3 and medicinal compositions containing the same. WO2004039782; 2004
   Google Scholar
• Nishioka C, Ikezoe T, Yang J, Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 2008;111:5086-92
   PubMed Web of Science ®Google Scholar
• Komeno Y, Kurokawa M, Imai Y, Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia 2005;19:930-5
   PubMed Web of Science ®Google Scholar
• Nishiyama U, Yoshino T, Ozai M, Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. Leuk Res 2006;30:1541-6
   PubMed Web of Science ®Google Scholar
• Array Biopharma. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors. WO2008121687; 2008
   Google Scholar
• Lopes De Menezes DE, Peng J, Garrett EN, CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91
   PubMed Web of Science ®Google Scholar
• Merck. Tyrosine kinase inhibitors. WO2003020699; 2003
   Google Scholar
• Merck. Orally active salts with tyrosine kinase activity. WO2002032861; 2002
   Google Scholar
• BASF. Tricyclic pyrazole derivatives. WO2000027822; 2000
   Google Scholar
• Murata K, Kumagai H, Kawashima T, Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003;278:32892-8
   PubMed Web of Science ®Google Scholar
• SuperGen. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same. US20080226747; 2008
   Google Scholar
• Xanthus Pharmaceuticals. Imidazoacridine compounds for treating FLT3-mediated disorders. WO2008016665; 2008
   Google Scholar
• Kinetek. Heteropolycyclic inhibitors of protein kinases. US6514972; 2003
   Google Scholar
• Zeng Z, Samudio IJ, Zhang W, Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006;66:3737-46
   PubMed Web of Science ®Google Scholar
• Novartis. Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases. WO2003099771; 2003
   Google Scholar
• Novartis. Diaryl urea derivatives in the treatment of protein kinase dependent diseases. WO2005051366; 2005
   Google Scholar
• Weisberg E, Roesel J, Bold G, Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 2008;112:5161-70
   PubMed Web of Science ®Google Scholar
• TargeGen. Bi-aryl meta-pyrimidine inhibitors of kinases. WO2007053452; 2007
   Google Scholar
• Wernig G, Kharas MG, Okabe R, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20
   PubMed Web of Science ®Google Scholar
• Celltech. 5-cyano-2-aminopyrimidine derivatives. WO2000078731; 2000
   Google Scholar
• Emanuel S, Gruninger RH, Fuentes-Pesquera A, A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 2004;66:635-47
   PubMed Web of Science ®Google Scholar
• Janssen. Aminopyrimidines as kinase modulators. WO2006135719; 2006
   Google Scholar
• Gaul MD, Xu G, Kirkpatrick J, 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors. Bioorg Med Chem Lett 2007;17:4861-5
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kogyo. Protein kinase inhibitors. WO2007032445; 2007
   Google Scholar
• Kyowa Hakko Kogyo. Anti-tumor agent. WO2005095382; 2005
   Google Scholar
• Ishida H, Isami S, Matsumura T, Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. Bioorg Med Chem Lett 2008;18:5472-7
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Shiotsu Y, Ozeki K, A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res 2007;13:4575-82
   PubMed Web of Science ®Google Scholar
• Rigel Pharmaceuticals. Cycloalkyl substituted pyrimidinediamine compounds and their uses. WO2005118544; 2005
   Google Scholar
• Mclaughlin J, Markovtsov V, Li H, Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136:99-113
   PubMed Web of Science ®Google Scholar
• S*Bio. Heterocycloalkyl substituted pyrimidine derivatives. WO2008140421; 2008
   Google Scholar
• Abbott. Substituted 7, 8-dihydro-1h-pyrimido [4,5-b] [1,4] diazepin-4-amines as kinase inhibitors. WO2006124813; 2006
   Google Scholar
• Gracias V, Ji Z, Akritopoulou-Zanze I, Scaffold oriented synthesis. Part 2: design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2008;18:2691-5
   PubMed Web of Science ®Google Scholar
• Ambit Biosciences. Urea derivatives as kinase modulators. WO2005048948; 2005
   Google Scholar
• Janssen. Method of inhibiting FLT3 kinase. WO2007048088; 2007
   Google Scholar
• Manthey CL, Johnson DL, Illig CR, JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 2009;8:3151-61
   PubMed Web of Science ®Google Scholar
• Akinion Pharmaceuticals. Pyrazine derivatives and their use as protein kinase inhibitors. WO2009095399; 2009
   Google Scholar
• Eriksson A, Hoglund M, Lindhagen E, Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia. Biochem Pharmacol 2010;80:1507-16
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-15
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40
   PubMed Web of Science ®Google Scholar
• Kelly L, Clark J, Gilliland DG. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Curr Opin Oncol 2002;14:10-18
   PubMed Web of Science ®Google Scholar
• Kelly LM, Liu Q, Kutok JL, FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002;99:310-18
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Engh RA, Aberg E, FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69:3032-41
   PubMed Web of Science ®Google Scholar
• Cools J, Mentens N, Furet P, Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004;64:6385-9
   PubMed Web of Science ®Google Scholar
• Heidel F, Solem FK, Breitenbuecher F, Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006;107:293-300
   PubMed Web of Science ®Google Scholar
• Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-22
   PubMed Web of Science ®Google Scholar